Nucleolar organizer region counts predict complete remission, remission duration, and survival in adult acute myelogenous leukemia patients

被引:13
|
作者
Pich, A
Chiusa, L
Audisio, E
Marmont, F
机构
[1] Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Sect Pathol, I-10126 Turin, Italy
[2] S Giovanni Hosp, Div Hematol, Turin, Italy
关键词
D O I
10.1200/JCO.1998.16.4.1512
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The analysis of the nucleolar organizer regions (AgNORs) was performed in patients with acute myelogenous leukemia (AML) to verify the role of cell proliferation in predicting complete remission (CR) and survival, Materials and Methods: Bone marrow biopsies from 40 adult patients with AML were stained with the argyrophilic method, The mean AgNOR number (AgNOR count) was calculated for each case, After induction therapy, patients who achieved CR received intensive consolidation; two underwent autologous and four allogeneic bone marrow transplantations (BMT). Results: The mean AgNOR count for the whole series was 6.6 (SD = 1.35); it was higher in CR patients than in resistant ones (P = .02), The median duration of CR was 26 months for patients with an AgNOR count greater than 6.6, but only 6 months for those with lower counts (P = .01). Sixteen patients who achieved a CR relapsed and 14 reached a second CR; the median duration of second CR was 16 months for patients with AgNOR count greater than 6.6, but only 5 months for those with lower counts (P = .01), The median survival time for the whole series was 14 months, with 30% of patients alive and in continuous CR at 103 months, Survival was longer for patients with an AgNOR count greater than 6.6 (33 months) than for those with lower counts (6 months; P = .0009), In multivariate analysis, when CR was excluded from the model, AgNOR count appeared as an independent prognostic variable (P = .005), Conclusion: AgNOR analysis is a suitable method to assess cell proliferation in bone marrow biopsies and can predict CR, remission duration, and survival in AML patients, (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:1512 / 1518
页数:7
相关论文
共 50 条
  • [1] 5 YEAR SURVIVAL AND REMISSION DURATION IN ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
    KEATING, MJ
    BODEY, GP
    MCCREDIE, KB
    FREIREICH, EJ
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 416 - 416
  • [2] PROGNOSTIC FACTORS AFFECTING REMISSION, REMISSION DURATION, AND SURVIVAL IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA
    BRANDMAN, J
    BUKOWSKI, RM
    GREENSTREET, R
    HEWLETT, JS
    HOFFMAN, GC
    [J]. CANCER, 1979, 44 (03) : 1062 - 1065
  • [3] ARGYROPHILIC NUCLEOLAR ORGANIZER REGION COUNTS PREDICT SURVIVAL IN THYMOMA
    PICH, A
    CHIARLE, R
    CHIUSA, L
    PALESTRO, G
    [J]. CANCER, 1994, 74 (05) : 1568 - 1574
  • [4] SPONTANEOUS REMISSION IN ACUTE MYELOGENOUS LEUKEMIA IN THE ADULT
    LACHANT, NA
    GOLDBERG, J
    NELSON, DA
    GOTTLIEB, AJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04): : 687 - 692
  • [5] Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia
    Lee, S
    Tallman, MS
    Oken, MM
    Cassileth, PA
    Bennett, JM
    Wiernik, PH
    Rowe, JM
    [J]. LEUKEMIA, 2000, 14 (08) : 1345 - 1348
  • [6] Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia
    S Lee
    MS Tallman
    MM Oken
    PA Cassileth
    JM Bennett
    PH Wiernik
    JM Rowe
    [J]. Leukemia, 2000, 14 : 1345 - 1348
  • [7] Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy
    Vey, N
    Keating, M
    Giles, F
    Cortes, J
    Beran, M
    Estey, E
    [J]. BLOOD, 1999, 93 (09) : 3149 - 3150
  • [8] DURATION OF COMPLETE REMISSION AND IMMUNOCOMPETENCE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    GARAY, GE
    SASIAIN, MDC
    PAVLOVSKY, S
    EPPINGERHELFT, M
    [J]. MEDICINA-BUENOS AIRES, 1976, 36 (06) : 565 - 566
  • [9] Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia.
    Tallman, MS
    Lee, S
    Oken, MM
    Cassileth, PA
    Bennett, JM
    Wiernik, PH
    Rowe, JM
    [J]. BLOOD, 1999, 94 (10) : 224B - 224B
  • [10] PROGNOSTIC FACTORS AFFECTING REMISSION INDUCTION AND DURATION IN ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
    VOGLER, WR
    WINTON, EF
    GORDON, DS
    JARRELL, R
    LEFANTE, J
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 489 - 489